Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus

Pharmacogenetics

Volumn 10, Issue 1, 2000, Pages 85-89

  Imai, Jun ^a   Ieiri, Ichiro ^a,c   Mamiya, Kohsuke ^a,b   Miyahara, Sayaka ^a   Furuumi, Hiroyasu ^a   Nanba, Eiji ^d   Yamane, Masayuki ^c   Fukumaki, Yasuyuki ^a   Ninomiya, Hideaki ^b   Tashiro, Nobutada ^b   Otsubo, Kenji ^c   Higuchi, Shun ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

CYP2C9; Genetic analysis; Japanese; New mutations; Polymorphism

Indexed keywords

CYTOCHROME P450 2C9;

ARTICLE; CLINICAL ARTICLE; DRUG METABOLISM; EPILEPSY; GENE LOCUS; GENETIC POLYMORPHISM; HUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; AMINO ACID SUBSTITUTION; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; EXONS; HUMANS; JAPAN; MUTATION; PHENYTOIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0034051119     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200002000-00011     Document Type: Article

References (13)

1. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-58.
2. de Morals SMF, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun 1993; 194:194-201.
3. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5:389-392.
4. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992; 267:83-90.
5. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9, in a Japanese population. Ther Drug Monit 1998; 20:243-247.
6. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult epileptic patients; studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39:1317-1323.
7. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62:287-292.
8. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30:3247-3255.
9. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.
10. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang Z-Y, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
11. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63:519-528.
12. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, et al. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289:533-538.
13. Wang S-L, Huang J, Lai M-D, Tsai J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5:37-42.